138 related articles for article (PubMed ID: 6753108)
1. The correlation between gastric emptying time and the response of GIP and enteroglucagon to oral glucose in duodenal ulcer patients.
Lauritsen KB; Frederiksen HJ; Uhrenholdt A; Holst JJ
Scand J Gastroenterol; 1982 Jun; 17(4):513-6. PubMed ID: 6753108
[TBL] [Abstract][Full Text] [Related]
2. The response of gastric inhibitory polypeptide (GIP) and insulin to glucose in duodenal ulcer patients.
Lauritsen KB; Moody AJ
Diabetologia; 1978 Mar; 14(3):149-53. PubMed ID: 658630
[TBL] [Abstract][Full Text] [Related]
3. Stimulation of gastric inhibitory polypeptide in normal and duodenal ulcer patients.
Cataland S; O'Dorisio TM; Brooks R; Mekhjian HS
Gastroenterology; 1977 Jul; 73(1):19-22. PubMed ID: 863190
[TBL] [Abstract][Full Text] [Related]
4. Serum gastric inhibitory polypeptide (GIP) in duodenal ulcer disease: relationship to glucose tolerance, insulin, and gastrin release.
Arnold R; Creutzfeldt W; Ebert R; Becker HD; Börger HW; Schafmayer A
Scand J Gastroenterol; 1978; 13(1):41-7. PubMed ID: 635445
[TBL] [Abstract][Full Text] [Related]
5. Enteroglucagon and GIP after oral glucose in patients with prolactinoma and acromegaly.
Cassar J; Ghatei MA; Sarson DL; Joplin GF; Mashiter K; Bloom SR
Clin Endocrinol (Oxf); 1983 Jan; 18(1):95-102. PubMed ID: 6342859
[TBL] [Abstract][Full Text] [Related]
6. Glucose-induced GIP levels in patients with insulinoma.
Tamburrano G; Lala A; Mauceri M; Leonetti F; Andreani D
Horm Metab Res; 1984 Dec; 16 Suppl 1():200-3. PubMed ID: 6099816
[TBL] [Abstract][Full Text] [Related]
7. Gut hormone profile and gastric emptying in the dumping syndrome. A hypothesis concerning the pathogenesis.
Lawaetz O; Blackburn AM; Bloom SR; Aritas Y; Ralphs DN
Scand J Gastroenterol; 1983 Jan; 18(1):73-80. PubMed ID: 6372067
[TBL] [Abstract][Full Text] [Related]
8. Different response of gastric inhibitory polypeptide to glucose and fat from duodenum and jejunum.
Schattenmann G; Ebert R; Siewert R; Creutzfeldt W
Scand J Gastroenterol; 1984 Mar; 19(2):260-6. PubMed ID: 6372074
[TBL] [Abstract][Full Text] [Related]
9. Gastric inhibitory polypeptide (GIP) and insulin release in duodenal ulcer patients.
Cataland S; O'Dorisio TM; Crockett SE; Mekhjian HS
J Clin Endocrinol Metab; 1978 Sep; 47(3):615-9. PubMed ID: 400727
[TBL] [Abstract][Full Text] [Related]
10. The evidence for the regulatory role of endogenous GIP as a glucose dependent insulinotropic hormone in patients with duodenal ulcer.
Takemura J; Seino Y; Yamamura T; Yoshiya K; Ishikawa Y; Itoh N; Imura H
Clin Endocrinol (Oxf); 1983 Sep; 19(3):345-53. PubMed ID: 6354520
[TBL] [Abstract][Full Text] [Related]
11. [The relationship between oral glucose tolerance and gastric emptying in duodenal ulcer patients (author's transl)].
Bittner R; Beger HG; Meves M
Chir Forum Exp Klin Forsch; 1980; ():213-6. PubMed ID: 7389458
[TBL] [Abstract][Full Text] [Related]
12. Effect of soya bean oil on symptoms, gastric emptying and gut hormone release in patients with postvagotomy symptoms.
Lawaetz O; Bloom SR; Stimpel H; Siemssen OJ
Ann Chir Gynaecol; 1986; 75(6):308-13. PubMed ID: 3555275
[TBL] [Abstract][Full Text] [Related]
13. Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP.
Theodorakis MJ; Carlson O; Michopoulos S; Doyle ME; Juhaszova M; Petraki K; Egan JM
Am J Physiol Endocrinol Metab; 2006 Mar; 290(3):E550-9. PubMed ID: 16219666
[TBL] [Abstract][Full Text] [Related]
14. Release of gastric inhibitory polypeptide and insulin in response to intrajejunal glucose in duodenal ulcer patients before and after truncal vagotomy.
Lauritsen KB; Moesgaard F; Nielsen ML; Jensen SL
Scand J Gastroenterol; 1982 Jun; 17(4):507-11. PubMed ID: 6753107
[TBL] [Abstract][Full Text] [Related]
15. [The effect of selective proximal vagotomy on gastrin, GIP and insulin blood levels in patients with duodenal ulcer].
Börger HW; Schafmayer A; Becker HD
Chir Forum Exp Klin Forsch; 1978; (1978):25-9. PubMed ID: 752595
[TBL] [Abstract][Full Text] [Related]
16. Gastric inhibitory polypeptide does not inhibit gastric emptying in humans.
Meier JJ; Goetze O; Anstipp J; Hagemann D; Holst JJ; Schmidt WE; Gallwitz B; Nauck MA
Am J Physiol Endocrinol Metab; 2004 Apr; 286(4):E621-5. PubMed ID: 14678954
[TBL] [Abstract][Full Text] [Related]
17. GIP, incretin and gastrointestinal disease.
Lauritsen KB
Dan Med Bull; 1983 Jun; 30(4):205-14. PubMed ID: 6347538
[No Abstract] [Full Text] [Related]
18. Discrepant performance on oral and intravenous glucose tolerance tests: the role of gastric inhibitory polypeptide.
Elahi D; Andersen DK; Tobin JD; Andres R
J Clin Endocrinol Metab; 1981 Jun; 52(6):1199-203. PubMed ID: 7014599
[TBL] [Abstract][Full Text] [Related]
19. Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes.
Nauck MA; El-Ouaghlidi A; Gabrys B; Hücking K; Holst JJ; Deacon CF; Gallwitz B; Schmidt WE; Meier JJ
Regul Pept; 2004 Nov; 122(3):209-17. PubMed ID: 15491793
[TBL] [Abstract][Full Text] [Related]
20. Gastric inhibitory polypeptide (GIP) and insulin release in response to oral and intravenous glucose in uremic patients.
Lauritzen JB; Lauritsen KB; Olsen ME; Timmerman I
Metabolism; 1982 Nov; 31(11):1096-9. PubMed ID: 6752641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
